We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Genprex Inc (GNPX) USD0.001

Sell:$2.30 Buy:$2.62 Change: $0.11 (4.31%)
Market closed |  Prices as at close on 20 May 2024 | Switch to live prices |
Sell:$2.30
Buy:$2.62
Change: $0.11 (4.31%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 May 2024 | Switch to live prices |
Sell:$2.30
Buy:$2.62
Change: $0.11 (4.31%)
Market closed |  Prices as at close on 20 May 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.

Contact details

Address:
1601 Trinity Street
Bldg. B, Suite 3.322
AUSTIN
78712
United States
Telephone:
+1 (512) 5377997
Website:
https://www.genprex.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GNPX
ISIN:
US3724462037
Market cap:
$5.35 million
Shares in issue:
2.10 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ryan Confer
    President, Chief Executive Officer, Chief Financial Officer, Director
  • Catherine Vaczy
    Executive Vice President, General Counsel, Chief Strategy Officer
  • Suzanne Thornton-Jones
    Senior Vice President - Regulatory Affairs
  • Hemant Kumar
    Chief Manufacturing and Technology Officer
  • Mark Berger
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.